SABCS: Laser Ablation a Possible Alternative Breast Cancer Therapy
Laser ablation procedure shows promise on breast cancer tumors up to 2 cm in diameter, but more study is needed.
Diagnosis & Disease Information
Impact of adding bevacizumab to presurgery chemotherapy for triple-negative breast cancer varies
The addition of bevacizumab to standard presurgery chemotherapy showed greater benefit in those whose cancers were classified as basal-like by gene expression assay, compared with those whose cancers were nonbasal-like.
Breast cancer has different biological characteristics and outcomes in men and women
Results from the largest series of male breast cancer cases ever studied shows improvement in male survival, but not equal to that seen in women with breast cancer.
Multigene test can predict risk of recurrence for women with ductal carcinoma in situ
A multigene test was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), according to data from a large study.
SABCS: Novel breast cancer drugs show promise in early trials
Pictilisib and pembrolizumab may prolong survival for women with advanced breast cancer, according to data from preliminary studies.
SABCS: Male breast cancer prognosis falls behind that for women
Although survival in male breast cancer has improved, treatment lags behind when compared to the cancer therapy women receive.
SABCS: Combined therapy can help younger breast cancer patients
Adding tamoxifen to ovarian suppression doesn’t provide a significant benefit over tamoxifen alone among premenopausal women with hormone receptor-positive early breast cancer, but the addition of ovarian suppression does benefit some of these women.
Trastuzumab benefit predicted by high levels of immune cells in breast cancer tumors
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
PIK3CA gene mutations make some breast cancers resistant to treatment
Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
Innovative clinical trial design is a new paradigm in breast cancer research
The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.
- Loading...
Loading...
Next post in Web Exclusives
Loading... 
Loading...